Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.
An association was found between the presence of the 20210 A allele and elevated prothrombin levels and Elevated pro thirdrombin itself also was found to be a risk factor for venous thrombosis. Expand
Mutation in blood coagulation factor V associated with resistance to activated protein C
It is demonstrated that the phenotype of APC resistance is associated with hetero-zygosity or homozygosity for a single point mutation in the factor V gene which predicts the synthesis of a factor V molecule that is not properly inactivated by APC. Expand
A method to determine the optimal intensity of oral anticoagulant therapy.
- F. Rosendaal, S. Cannegieter, F. V. D. van der Meer, E. Briët
- Thrombosis and haemostasis
- 1 March 1993
This method allows the determination of the optimal pharmacological effects of anticoagulation, which can form a rational starting point for choosing the target levels in subsequent clinical trials. Expand
Venous thrombosis: a multicausal disease
- F. Rosendaal
- The Lancet
- 3 April 1999
The risk factors for venous thrombosis differ from those for arterial vascular disease, particularly the role of coagulation abnormalities, and the resultant gene-gene and gene-environment interactions between risk factors are the key to the understanding of why a certain person develops thromBosis at a specific point in time. Expand
Malignancies, prothrombotic mutations, and the risk of venous thrombosis.
Patients with cancer have a highly increased risk of venous thrombosis especially in the first few months after diagnosis and in the presence of distant metastases, which is a common complication in patients with cancer. Expand
Optimal oral anticoagulant therapy in patients with mechanical heart valves.
- S. Cannegieter, F. Rosendaal, A. Wintzen, F. V. D. van der Meer, J. Vandenbroucke, E. Briët
- The New England journal of medicine
- 6 July 1995
The intensity of anticoagulant therapy for patients with prosthetic heart valves is optimal when the INR is between 2.5 and 4.9, and the level at which thromboembolic complications are effectively prevented without excessive bleeding is recommended. Expand
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis
High factor VIII concentrations are common and represent a clear increase in risk of thrombosis, similar to the risks conferred by deficiencies of the coagulation-inhibiting proteins and activated protein C resistance. Expand
Incidence and mortality of venous thrombosis: a population‐based study
- I. A. Næss, S. Christiansen, P. Romundstad, S. Cannegieter, F. Rosendaal, J. Hammerstrøm
- Journal of thrombosis and haemostasis : JTH
- 1 April 2007
This data indicates that venous thrombosis in women under the age of 40 is more prone to bleeding than in men, and the incidence ofVT among women aged 40 and over is higher than in women aged 50 and over. Expand
Genetic variants associated with subjective well-being, depressive symptoms and neuroticism identified through genome-wide analyses
Across the phenotypes, loci regulating expression in central nervous system and adrenal or pancreas tissues are strongly enriched for association and the two loci associated with depressive symptoms replicate in an independent depression sample. Expand
High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
It is assumed that most individuals homozygous for factor V Leiden will experience at least one thrombotic event in their lifetime, which implies that the increased risk of venousThrombosis with age becomes most pronounced in older patients, both for heterozygous and Homozygous individuals. Expand